Skyepharma booklet of services

Using Veratrak's platform, the CDMO will have full oversight of data, including an audit trail of data and document processes

In this article, Mathieu Degomme, PharmD, Pharmaceutical Development Project Manager, and Aline Moulin, PhD, Pharmaceutical Development Director, both of Skyepharma, outline three case studies from recent early-stage development programmes to illustrate what kind of complex tablets can be developed to meet specific target dissolution profiles for versatile applications.

R&D : Mechanical resistance of pharmaceutical press coated tablets (tab-in-tab): characterization and link with material and process parameters.

Through 25 years of involvement and achievements in the pharmaceutical industry, Skyepharma’s development and manufacturing facility is a leader in the field of classic and complex oral solid dosage forms.

Several ongoing development programs are dedicated to the manufacturing of orphan drugs intended for both US and European patients. Skyepharma team is proud to work on orphan drugs development projects.

This article describes the robustness of Skyepharma's supply chain. The delivery of our products has not been impacted during this COVID-19 pandemic. Discover how!

Skyepharma has extended its serialisation and aggregation service to ‘hard to reach’ countries like Russia and Brazil. We are now able to offer serialized and aggregated supplies to Russia.

Skyepharma is a full CDMO. We have an analytical service that covers all aspects from development to manufacturing. Packaging, raw materials and finished products are all controlled by this service.

Aline Moulin,  Head of New Product Introduction Department (NPI), presented different case studies during the Pharma Insight Briefings 2018 (CPhI Worldiwide): "COMPACTION SIMULATION AS A POWERFUL QUALITY BY DESIGN (QbD) TOOL How Skyepharma can help you to shorten the time and reduce the cost of pharmaceutical development programmes"

The serialization system allows the verification of a drug's compliance from the distribution to the delivery then to the patient. This article explains the serialization and aggregation implemented at Skyepharma.

David Lescuyer, Executive Vice President and Frederic Checo, Pharmaceutical Development Leader, both from Skyepharma speaks with CPhI TV at CPhI Worldwide in Madrid, Spain

Since 2018, oral dosage CDMO Skyepharma radically updated and expanded its packaging capabilities, opening new packaging lines equipped for serialization and aggregation.

Lucile Kowalsky, Project Manager in the New Product Introduction (NPI) department presented a case study during the Pharma Insight Briefings (CPhI Worldwide 2017) : "Quality by Design and Expertise:Accelerating time to market of complex oral solid dosage Accelerating time to market."

For the 2019 edition of Pharmapack, the magazine “Emballages Magazine” has decided to publish a journal dedicated to the traceability of pharmaceutical products.

Over the last two years a significant and highly successful transformation has taken place at the Skyepharma site in Lyon, France.

.Skyepharma's interview shows the company's growth since last year. David Lescuyer, Florence Lemoult and Frédéric Checot are the interviewees

At Skyepharma we are proud to announce the creation of a new Customer Service department.

We are able to develop analytical methods in a limited time, from bibliography study, screening parameters and conditions to sample preparation and assessment of robustness.

SKYEPHARMA, a subsidiary of the VECTURA group, has chosen its St Quentin Fallavier site, in Lyon area, to develop its pharmaceutical packaging activities, with strategic investments in two new complete lines for bottle and blister packaging, including serialization and aggregation.

For Skyepharma, being reliable means taht we are able to meet our customers' needs on time and to the expected level of quality. Skyepharma your reliable CDMO for faster time to market without compromising on product quality

Skyepharma Production SAS, (“Skyepharma”) the contract development and manufacturing organization (CDMO) specialists in the development, manufacturing and packaging of classic and complex oral solid dosage forms, and Therabel, a privately-owned pharmaceutical group today announce their strengthened partnership for the production of Therabel’s solid form manufacturing.

For Skyepharma, to be agile qualifies our ability to mobilize experts and work together to solve complex efficiently and rapidly. Skyepharma, your AGILE CDMO partner for tailor-made solutions.

Skyepharma is a french fully integrated CDMO with expertise in classic & complex oral solid dosage forms offering : Development, Manufacturing and Packaging services.  As a fully integrated CDMO Skyepharma provides tailor-made solutions to customers by positioning itself as an integrated partner offering a wide range of premium services.  
Our experienced team of specialists works to optimize target product profile and drug development program from early formulation development, scale-up, manufacturing and packaging to regulatory support.

- Bottle packaging - Blister packaging 
- Stick-packs 
- Serialization & aggregation services (Seavision systems)